Pay in 4 interest-free payments of $6.74 Learn more
Ships within 48 hours · Estimated delivery Sep 4 - Sep 9
These results demonstrate that SPAE effectively reduces DEX-induced DNA damage in hepatic tissues, with the 800 mg/kg dose offering greater genoprotective effects than 400 mg/kg (Table 4
Fukase, H
NCT05929066 ClinicalTrials.gov
Retatrutide (LY-3437943) is an investigational triple-receptor agonist targeting GLP-1, GIP, and glucagon receptors, extending beyond the mechanisms of currently approved single- and dual-agonist therapies
It was developed to stimulate the release of growth hormone (GH) from the pituitary gland without significantly affecting cortisol or prolactin levels
US$ 29.27
US$ 29.45
US$ 22.51
US$ 26.73
US$ 26.62
